fda glp-1 safety warning september 2025 8, 2025: launches an import alert listing safe manufacturers – Partnership for Safe Medicines GLP-1 RA prescription trends: January

J., El Essawy, B., Jang, J., Loretelli, C., DAddio, F., Berra, C., Ben Nasr, M., Zuccotti, G., & Fiorina, P

Key findings More than half of GLP-1 users, 52%, report that they spend less money on dining out since starting the medications

These symptoms can lead to fluid loss or reduced water intake, resulting in dehydration, a common trigger for headaches

Invest in a small or medium sized emerging biotechnology firms that are running clinical trials of novel approaches

It is also developing KAI-4729, a triple agonist, and KAI-7535, an investigational oral GLP-1 product

Then, further screening process was applied, guided by inclusion criteria of all the clinical trials that were involved the use of GLP-1 as a primary intervention for GDM, where all other studies were excluded